Previous close | 13.05 |
Open | N/A |
Bid | 17.10 |
Ask | 21.30 |
Strike | 85.00 |
Expiry date | 2024-11-15 |
Day's range | 13.05 - 13.05 |
Contract range | N/A |
Volume | |
Open interest | 1 |
ALISO VIEJO, Calif., June 14, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its 2.75% Convertible Senior Notes due 2027 (the "Existing Convertible Notes"). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million princi
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.